Form 4 for HCWB HCW Biologics Inc.
Accepted 2023-12-11 00:00:00 ET · period of report 2023-12-08 · accession 0001209191-23-058081 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-12-11 | 2023-12-08 | HCWB | Flowers Lee | SVP of Business Development | M - OptEx | $0.14 | +7,501 | 118.8K | +7% | +$1,050 |
| D | 2023-12-11 | 2023-12-08 | HCWB | Flowers Lee | SVP of Business Development | M - OptEx | $0.00 | -7,501 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-12-08 | M | A | 7,501 | $0.14 | 118,809 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2023-12-08 | M | D | 7,501 | $0.00 | 0 | D | $0.14 · — to 2029-09-18 | 7,501 Common Stock | (F1) 20% of the total shares subject to the stock option grant vested on September 16, 2020; 20% of the total shares subject to the stock option grant vested on September 16, 2021; 25% of the total shares subject to the stock option grant vested on September 16, 2022; and 35% of the total shares subject to the stock option grant vested on September 16, 2023. |